Insider and congress filings
Incyte Corporation (INCY)
About Incyte Corporation
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- William J. Meury
- Employees
- 2,844
- Listed since
- Nov 4, 1993
- Market value
- $25.5B
- Price to earnings
- 15.5
- Earnings per share
- $8.05
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 27, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 28, 2026 | $3.09 | $2.15 | $1.7B | $1.5B | EPS beatRevenue beat |
| Q1 FY2026reported Apr 28, 2026 | $1.81 | $1.34 | $1.3B | $1.2B | EPS beatRevenue beat |
| Q4 FY2025reported Feb 10, 2026 | $1.80 | $1.90 | $1.5B | $1.4B | EPS missRevenue beat |
| Q3 FY2025reported Oct 28, 2025 | $2.26 | $1.66 | $1.4B | $1.4B | EPS beatRevenue in line |
| Q2 FY2025reported Jul 29, 2025 | $1.57 | $1.39 | $1.2B | $1.3B | EPS beatRevenue miss |
| Q1 FY2025reported Apr 29, 2025 | $1.16 | $1.01 | $1.1B | $1.2B | EPS beatRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 28, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| William J. MeuryChief Executive Officer | $647K | $27.5M | $3.9M | $32.1M |
| Mohamed IssaExecutive Vice President and Head of U.S. Commercial | $690K | $7.9M | $2.0M | $10.6M |
| Pablo J. CagnoniPresident and Global Head of Research and Development | $967K | $5.0M | $2.9M | $8.8M |
| Steven H. SteinExecutive Vice President, Chief Medical Officer and He | $835K | $3.5M | $2.0M | $6.3M |
| Thomas TrayVice President, Chief Accounting Officer and Principal | $358K | $306K | $326K | $990K |
The summary compensation table from the 2025 proxy statement, current executives only. 2 executives who have since left the company are named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Baker Bros. Advisors LP | $3.5B | 30,762,330 | +0.1% | 15.35% |
| Blackrock, Inc. | $2.0B | 18,032,718 | -5.0% | 9.00% |
| Dodge & Cox | $1.4B | 11,957,326 | -2.4% | 5.97% |
| Vanguard Capital Management LLC | $1.2B | 11,024,289 | +0.9% | 5.50% |
| State Street Corp | $1.1B | 9,722,336 | +0.8% | 4.85% |
| Vanguard Portfolio Management LLC | $883.2M | 7,791,091 | +0.4% | 3.89% |
| AQR Capital Management LLC | $603.2M | 5,320,901 | -8.4% | 2.66% |
| Geode Capital Management, LLC | $536.5M | 4,750,735 | +1.0% | 2.37% |
| LSV Asset Management | $467.5M | 4,123,759 | +5.2% | 2.06% |
| Invesco Ltd. | $462.6M | 4,080,461 | +5.4% | 2.04% |
| Wellington Management Group LLP | $405.3M | 3,575,521 | +9.5% | 1.78% |
| Renaissance Technologies LLC | $398.1M | 3,512,132 | -3.8% | 1.75% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
10 filings of 339 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| Pablo J. CagnoniPresident, Global Head of R&D | Sold | 10,801 | $125.56 | $1.4M | Aug 19, 2026 | 1d |
| Pablo J. CagnoniPresident, Global Head of R&D | Sold | 10,803 | $120.04 | $1.3M | Aug 12, 2026 | 2d |
| Pablo J. CagnoniPresident, Global Head of R&D | Sold | 10,640 | $122.69 | $1.3M | Aug 5, 2026 | 2d |
| Patrick A. MayesEVP & Chief Scientific Officer | Sold | 2,207 | $123.99 | $274K | Aug 5, 2026 | 2d |
| Patrick A. MayesEVP & Chief Scientific Officer | Sold · 11 lines | 41,899 | $119.46 | $5.0M | Jul 31, 2026 | 4d |
| Pablo J. CagnoniPresident, Global Head of R&D | Sold | 15,888 | $119.70 | $1.9M | Jul 31, 2026 | 4d |
| Patrick A. MayesEVP & Chief Scientific Officer | Sold | 6,055 | $120.43 | $729K | Aug 3, 2026 | 1d |
| Steven H. SteinCMO & Head of Late-Stage Dev. | Sold | 1,877 | $114.73 | $215K | Jul 16, 2026 | 4d |
| Mohamed Khairie IssaEVP, Head of U.S. Commercial | Sold | 1,093 | $115.01 | $126K | Jul 16, 2026 | 4d |
| Steven H. SteinCMO & Head of Late-Stage Dev. | Sold | 28,237 | $113.05 | $3.2M | Jul 15, 2026 | 1d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in INCY
20 disclosures of 51 on record · median 22d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +32.2%S&P +3.2% · vs S&P 500 +29.1% | May 15, 2026 | Jun 9, 2026 | 25d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +31.2%S&P +12.6% · vs S&P 500 +18.7% | Mar 10, 2026 | Apr 7, 2026 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +39.5%S&P +20.7% · vs S&P 500 +18.9% | Mar 30, 2026 | Apr 7, 2026 | 8d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +24.7%S&P +9.8% · vs S&P 500 +14.9% | Jan 29, 2026 | Feb 6, 2026 | 8d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +97.5%S&P +28.2% · vs S&P 500 +69.3% | May 19, 2025 | Jun 10, 2025 | 22d |
| Robert Bresnahan | Stock | Sale | $1,001 - $15,000 | +100.8%S&P +29.1% · vs S&P 500 +71.7% | May 15, 2025 | May 31, 2025 | 16d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +79.6%S&P +24.3% · vs S&P 500 +55.3% | Feb 19, 2025 | Mar 6, 2025 | 15d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +73.0%S&P +28.1% · vs S&P 500 +44.8% | Jan 17, 2025 | Feb 6, 2025 | 20d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +66.1%S&P +30.2% · vs S&P 500 +35.9% | Nov 15, 2024 | Dec 5, 2024 | 20d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +95.5%S&P +43.1% · vs S&P 500 +52.4% | Aug 2, 2024 | Sep 6, 2024 | 35d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +144.0%S&P +50.8% · vs S&P 500 +93.2% | Apr 23, 2024 | May 6, 2024 | 13d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +119.2%S&P +46.6% · vs S&P 500 +72.6% | Mar 25, 2024 | Apr 5, 2024 | 11d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +129.3%S&P +67.0% · vs S&P 500 +62.3% | Dec 4, 2023 | Jan 4, 2024 | 31d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +120.1%S&P +75.6% · vs S&P 500 +44.6% | Oct 10, 2023 | Nov 8, 2023 | 29d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +114.3%S&P +79.3% · vs S&P 500 +35.0% | Oct 2, 2023 | Nov 8, 2023 | 37d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +99.4%S&P +70.9% · vs S&P 500 +28.5% | Sep 6, 2023 | Oct 6, 2023 | 30d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +103.7%S&P +74.1% · vs S&P 500 +29.6% | Jun 29, 2023 | Jul 11, 2023 | 12d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +100.2%S&P +76.1% · vs S&P 500 +24.1% | Jun 26, 2023 | Jul 11, 2023 | 15d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +95.7%S&P +83.1% · vs S&P 500 +12.6% | May 19, 2023 | Jun 12, 2023 | 24d |
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | +66.1%S&P +88.5% · vs S&P 500 -22.4% | Mar 6, 2023 | Apr 17, 2023 | 42d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
1 member · estimate, as of Sep 10, 20261 member reports a position (estimated). The largest estimated position is in the $1,001 - $15,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Robert Bresnahan | Republican · House | $1,001 - $15,000 | 0.1% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Awards, option exercises and gifts (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Ramitpal K. BasiEVP, Human Resources | Tax withholding | 504 | Aug 25, 2026 |
| Patrick A. MayesEVP & Chief Scientific Officer | Option exercise | 2,207 | Aug 5, 2026 |
| Patrick A. MayesEVP & Chief Scientific Officer | Option exercise | 37,089 | Jul 31, 2026 |
| Patrick A. MayesEVP & Chief Scientific Officer | Option exercise | 6,055 | Aug 3, 2026 |
| Michael James MorrisseyEVP, Head of Tech. Operations | Stock award | 15,425 | Jul 23, 2026 |
| Lee HeesonEVP, Head of Incyte Intl | Stock award | 28,921 | Jul 23, 2026 |
| William MeuryChief Executive Officer | Stock award | 184,376 | Jul 16, 2026 |
| Richard A. HoffmanEVP & General Counsel | Stock award | 57,805 | Jul 16, 2026 |
| Thomas TrayPrincipal Accounting Officer | Stock award | 6,913 | Jul 16, 2026 |
| Steven H. SteinCMO & Head of Late-Stage Dev. | Stock award | 76,592 | Jul 16, 2026 |
| Patrick A. MayesEVP & Chief Scientific Officer | Stock award | 46,244 | Jul 16, 2026 |
| Pablo J. CagnoniPresident, Global Head of R&D | Stock award | 104,772 | Jul 16, 2026 |
| Mohamed Khairie IssaEVP, Head of U.S. Commercial | Stock award | 61,418 | Jul 16, 2026 |
| Ramitpal K. BasiEVP, Human Resources | Stock award | 39,018 | Jul 16, 2026 |
| David H. GardnerEVP, Chief Strategy Officer | Stock award | 57,805 | Jul 16, 2026 |
| Pablo J. CagnoniPresident, Global Head of R&D | Tax withholding | 4,950 | Jul 15, 2026 |
| Pablo J. CagnoniPresident, Global Head of R&D | Tax withholding | 17,969 | Jul 14, 2026 |
| Patrick A. MayesEVP & Chief Scientific Officer | Tax withholding | 437 | Jul 14, 2026 |
| Patrick A. MayesEVP & Chief Scientific Officer | Tax withholding | 1,512 | Jul 15, 2026 |
| Thomas TrayPrincipal Accounting Officer | Tax withholding | 692 | Jul 14, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling INCY?
Across the 10 most recent open-market filings shown here, 0 were purchases and 10 were sales.
Which members of Congress have traded INCY?
Ro Khanna, Robert Bresnahan, Daniel S. Goldman disclosed INCY transactions in the filings shown here.
Which members of Congress hold INCY?
1 member of Congress reports a position in INCY in the estimate we hold as of Sep 10, 2026. The largest estimated position belongs to Robert Bresnahan. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is INCY in the S&P 500 or the Nasdaq 100?
Incyte Corporation is a current member of the S&P 500, per the membership list we hold as of Sep 10, 2026. Current members of either index get a page here whatever their filing history.
How quickly are INCY trades disclosed?
Insider filings on this page reached the public a median of 2 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 22 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.